Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2025-12-26 @ 12:41 AM
Study NCT ID:
NCT01001260
Status:
TERMINATED
Last Update Posted:
2019-06-11
First Post:
2009-10-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
PGD2 Formation in Vascular Injury
Sponsor:
University of Pennsylvania
Organization:
Study Overview
Official Title:
Biosynthesis of PGD2 in Vascular Injury
Status:
TERMINATED
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Unable to find subjects that met inclusion/exclusion criteria.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PGD2
Brief Summary:
To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.
Detailed Description:
A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans
B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.
B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| American Heart Association | None | None | View |